Cowen & Co. Maintains a Buy Rating on Kura Oncology (KURA)

By Jason Carr

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Kura Oncology (KURAResearch Report) today. The company’s shares opened today at $18.91.

According to, Shibutani is a 3-star analyst with an average return of 2.0% and a 41.1% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $28, a 48.1% upside from current levels. In a report issued on June 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $31 price target.

See today’s analyst top recommended stocks >>

Based on Kura Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.94 million. In comparison, last year the company had a GAAP net loss of $14.6 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.